截至2025年8月5日收盘，思创医惠股价报4.07元，较前一交易日下跌0.06元，跌幅1.45%。当日成交量 为571102手，成交额达2.34亿元。 风险提示：投资有风险，入市需谨慎。 思创医惠属于互联网服务和物联网领域，是一家专注于医疗信息化和智能医疗设备研发的企业。公司主 要业务包括医疗信息化整体解决方案、智能开放平台、物联网技术应用等。 来源：金融界 8月5日公司公告显示，已完成向苍南县山海数字科技有限公司出售医惠科技有限公司100%股权的交 易，交易对价为3亿元。山海数科已支付全部款项，医惠科技已完成工商变更登记手续。2025年一季 度，思创医惠实现收入4.09亿元，归母净利润-1956万元。 资金流向方面，8月5日主力资金净流出1965.04万元，占流通市值比为0.43%。近五日主力资金净流入 1028.29万元，占流通市值比为0.23%。 ...

Core Viewpoint - The independent financial advisor, Guojin Securities, has issued a verification opinion regarding the major asset sale and related transactions of Sichuang Medical Technology Co., Ltd, confirming compliance with relevant laws and regulations [1][2]. Group 1: Transaction Overview - The transaction involves the sale of 100% equity of Yihui Technology Co., Ltd by Sichuang Medical Technology to Cangnan Mountain Sea Digital Technology Co., Ltd [3]. - The transaction price is based on the asset evaluation report, amounting to RMB 299.5995 million [4][5]. - The transaction constitutes a major asset restructuring as it meets the criteria set forth in the restructuring management regulations [5][6]. Group 2: Financial Assessment - The assessed value of the total equity of Yihui Technology is RMB 236.1515 million, with an increase rate of 26.87% compared to the book value of RMB 185.0000 million [4][5]. - The total assets of Sichuang Medical and Yihui Technology are RMB 259,233.76 million and RMB 180,665.28 million respectively, indicating a ratio of 69.69% [5]. Group 3: Approval and Compliance - The necessary approvals and authorizations for the transaction have been obtained, and there are no pending decision-making or approval processes [6][7]. - The transfer of the target assets has been completed, with the registration of the assets under the buyer's name finalized [6][7]. Group 4: Management Changes - There have been changes in the board of directors and management personnel of both Sichuang Medical and Yihui Technology following the transaction [8]. - The first major shareholder, Lu Nan, signed the share transfer agreement, resulting in Cangnan County Finance Bureau indirectly holding an 11.33% stake, thus becoming the actual controller of the company [5][6]. Group 5: Risk and Compliance - Throughout the transaction process, there have been no instances of the company's funds or assets being occupied by the major shareholder or related parties [9]. - All related agreements and commitments have been fulfilled without any violations, ensuring compliance with legal and regulatory requirements [9][10].

Group 1 - The core opinion of the article is that the legal opinion issued by Beijing Deheng (Hangzhou) Law Firm confirms the legality and compliance of the major asset sale and related transactions of Sichuang Medical Technology Co., Ltd [1][4][14] - The transaction involves the transfer of 100% equity of Yihui Technology by Sichuang Medical to Shanhai Digital for a total price of 299.5995 million yuan [5][10] - The payment for the transaction will be made in cash, with the entire amount to be paid before the completion of the asset transfer [6][10] Group 2 - The legal opinion states that the transaction has received necessary approvals and authorizations from the company's board and shareholders [8][10][14] - The transfer of ownership for the assets has been completed, and the relevant registration procedures have been carried out [11][14] - There are no significant discrepancies between the actual situation of the transaction and the previously disclosed information [11][14] Group 3 - The company has confirmed that there have been no changes in the board of directors, supervisors, or senior management personnel of either the listed company or the target company since the disclosure of the restructuring report [12][14] - The transaction does not involve the transfer of debts and liabilities of the target company, and there have been no instances of fund occupation or guarantees provided to related parties during the transaction process [13][14] - All parties involved in the transaction are fulfilling their commitments and agreements as per the signed equity transfer agreement [13][14]

思创医惠公告，公司向苍南县山海数字科技有限公司出售持有的医惠科技有限公司100%股权，交易对 价为3亿元。截至公告披露日，交易对方已支付全部股权转让价款，公司已收到全部款项，并完成标的 资产过户手续。医惠科技于2025年8月5日完成工商变更登记手续，取得新的营业执照。本次交易构成重 大资产重组和关联交易。 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-085 思创医惠科技股份有限公司 关于重大资产出售暨关联交易实施完毕的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"）向苍南县山海数字科技有 限公司（以下简称"山海数科"）出售公司持有的医惠科技有限公司（以下简称 "医惠科技"或"标的公司"）100%股权，根据《上市公司重大资产重组管理办 法》（以下简称"《重组管理办法》"）的规定，上述交易事项构成重大资产重 组（以下简称"本次交易"）。根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）以及《深 圳证券交易所创业板股票上市规则》等法律、法规及规范性文件的相关规定，本 次交易构成关联交易。 公司分别于 2025 年 4 月 28 日、2025 年 5 月 29 日、2025 年 7 月 14 日、2025 年 7 月 30 日召开第六届董事会第五次会议、第六届董事会第七次会议、第六届 董事会第八次会议、2025 年第三次临时股东会，审议通过了与 ...

国金证券股份有限公司 关于 思创医惠科技股份有限公司 重大资产出售暨关联交易实施情况 之 独立财务顾问核查意见 独立财务顾问 二零二五年八月 声明 国金证券股份有限公司接受思创医惠科技股份有限公司董事会的委托，担任 本次思创医惠科技股份有限公司重大资产重组之独立财务顾问。 根据《公司法》《证券法》《重组管理办法》《26 号准则》等法律法规的相 关规定，按照证券行业公认的业务规范，本着诚实守信、勤勉尽责的精神，遵循 独立、客观、公正的原则，在认真审阅相关资料并充分了解本次交易行为的基础 上，本独立财务顾问出具了本核查意见。 本核查意见所依据的文件、材料由本次交易相关各方提供，本次交易相关各 方已承诺所提供文件和材料真实、准确和完整，不存在虚假记载、误导性陈述或 者重大遗漏。本独立财务顾问不承担由此引起的任何风险责任。 本独立财务顾问未委托或授权其他任何机构或个人提供未在本核查意见中 列载的信息和对本核查意见做任何解释或说明。 本核查意见不构成对思创医惠科技股份有限公司的任何投资建议或意见，本 独立财务顾问对投资者根据本核查意见作出的投资决策可能产生的风险，不承担 任何责任。本独立财务顾问特别提请广大投资者认真阅 ...

思创医惠科技股份有限公司 重大资产出售暨关联交易实施情况 报告书 独立财务顾问 二零二五年八月 上市公司声明 本公司及全体董事、监事、高级管理人员保证本报告书的内容真实、准确和 完整，并对本报告书的虚假记载、误导性陈述或者重大遗漏承担相应的法律责任。 本次重大资产重组的交易对方已出具承诺函，保证其为本次重大资产重组所 提供的信息不存在虚假记载、误导性陈述或者重大遗漏，并对所提供信息的真实 性、准确性和完整性承担相应的法律责任。 本次交易有关监管部门对本次交易事项所作的任何决定或意见，均不代表其 对本公司股票的价值或投资者收益的实质性判断或保证。任何与之相反的声明均 属虚假不实陈述。 本次交易完成后，公司经营与收益的变化由公司负责；因本次交易引致的投 资风险，由投资者自行负责。 投资者若对本报告书存在任何疑问，应咨询自己的股票经纪人、律师、专业 会计师、或其他专业顾问。 1 | 目录 | | --- | | 上市公司声明 1 | | --- | | 目录 2 | | 释义 3 | | 第一节 本次交易概况 5 | | 一、本次交易方案概述 5 | | 二、标的资产的评估及作价情况 5 | | 三、本次交易的性质 ...

北京德恒（杭州）律师事务所 关于 思创医惠科技股份有限公司 重大资产出售暨关联交易实施情况的 法律意见 浙江省杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 电话：0571-86508080 传真：0571-87357755 邮编：310020 | 一、 | 本次交易的方案 4 | | --- | --- | | 二、 | 本次交易的批准和授权 6 | | 三、 | 本次交易的实施过程 7 | | 四、 | 相关实际情况与此前披露的信息是否存在差异 8 | | 五、 | 董事、监事、高级管理人员的更换情况 8 | | 六、 | 本次交易实施过程中资金占用及关联担保的情形 9 | | 七、 | 本次交易相关协议及承诺的履行情况 9 | | 八、 | 本次交易的后续事项 9 | | 九、 | 结论意见 10 | 北京德恒（杭州）律师事务所 关于思创医惠科技股份有限公司 重大资产出售暨关联交易实施情况的法律意见 1.为出具本法律意见，本所律师对公司提供的与本次重大资产重组有关的文 件资料内容的真实性、准确性、完整性进行了审慎的核查和验证，就有关事项询 问了公司的相关人员并进行了必要的讨论。公司已向本 ...

Market Performance - As of August 1, the DRG/DIP concept increased by 1.87%, ranking second among concept sectors, with 19 stocks rising, including Saily Medical, Sichuang Medical, and Jiayuan Technology, which rose by 6.20%, 5.04%, and 5.00% respectively [1] - The top-performing concept sectors included Animal Vaccines at 2.22% and BC Batteries at 1.71%, while the worst performers included the China Shipbuilding System at -2.54% and Military Equipment Restructuring at -1.90% [2] Capital Flow - The DRG/DIP concept sector saw a net inflow of 109 million yuan, with 14 stocks receiving net inflows, and 10 stocks exceeding 10 million yuan in net inflow, led by Weining Health with a net inflow of 93.03 million yuan [2] - Other notable net inflows included Saily Medical at 33.50 million yuan, Rongke Technology at 31.92 million yuan, and Sichuang Medical at 30.87 million yuan [2] Stock Performance - The top stocks in the DRG/DIP concept based on net capital inflow included Weining Health with a 3.31% increase and a turnover rate of 9.45%, followed by Saily Medical at 6.20% and a turnover rate of 25.56% [3] - Other significant performers included Rongke Technology at 2.31% and Sichuang Medical at 5.04%, with respective net inflow ratios of 6.05% and 5.47% [3][4]

Group 1 - The assisted reproductive industry is experiencing a strong upward trend, with companies such as HanShang Group, FuYuan Pharmaceutical, and LiDeMan reaching their daily price limit [1] - Other companies in the sector, including GongTong Pharmaceutical, DaJia WeiKang, SiChuang YiHui, BoTuo Bio, BeiRui Gene, and MaiDi Technology, also saw significant increases in their stock prices [1]